334 related articles for article (PubMed ID: 21986224)
1. Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Stephenson AJ; Aprikian AG; Gilligan TD; Oldenburg J; Powles T; Toner GC; Waters WB
Urology; 2011 Oct; 78(4 Suppl):S444-55. PubMed ID: 21986224
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
3. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
4. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
6. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
7. Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Warde P; Huddart R; Bolton D; Heidenreich A; Gilligan T; Fossa S
Urology; 2011 Oct; 78(4 Suppl):S435-43. PubMed ID: 21986223
[TBL] [Abstract][Full Text] [Related]
8. Management of clinical stage I nonseminomatous germ-cell testis tumors.
Flechon A; Droz JP
Expert Rev Anticancer Ther; 2003 Feb; 3(1):21-30. PubMed ID: 12597346
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis.
Sogani PC
Urol Clin North Am; 1991 Aug; 18(3):561-73. PubMed ID: 1652171
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
11. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
13. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
14. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
15. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
17. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
18. Management of clinical stage I nonseminomatous germ cell testicular cancer.
Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
[TBL] [Abstract][Full Text] [Related]
19. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
20. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]